Publications by authors named "Andreas Kerschbaumer"

Claim this Profile
G
Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis.
Andreas Kerschbaumer, Marlene Steiner, Pascale Pruckner, Brigitte Wildner, Magdalena Maad

Ann Rheum Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.
Kevin L Winthrop, Joan Bathon, Andreas Kerschbaumer, John D Isaacs, Philip Mease

Ann Rheum Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis.
Andreas Kerschbaumer, Marlene Steiner, Suzanne Khalili, Azad Shehab, Alexander Jordanov

Arthritis Rheumatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statement.
Victoria Konzett, Josef S Smolen, Peter Nash, Kevin Winthrop, Daniel Aletaha, Andreas Kerschbaumer

Ann Rheum Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement.
Victoria Konzett, Josef S Smolen, Peter Nash, Daniel Aletaha, Kevin Winthrop, Andreas Kerschbaumer

Ann Rheum Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, Daniel Aletaha, Thomas Dörner

Ann Rheum Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aerosol particle number concentration, ultrafine particle number fraction, and new particle formation measurements near the international airports in Berlin, Germany - First results from the BEAR study.
Simonas Kecorius, Susanne Sues, Leizel Madueño, Alfred Wiedensohler, Ulf Winkler, Andreas Kerschbaumer

Environ Int· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos

Ann Rheum Dis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Andreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, Heidi Bertheussen, Xenofon Baraliakos

Ann Rheum Dis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld

Ann Rheum Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review.
Elvis Hysa, Milena Bond, Lisa Ehlers, Dario Camellino, Louise Falzon, Andreas Kerschbaumer

Rheumatology (Oxford)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.
Christian Dejaco, Andreas Kerschbaumer, Daniel Aletaha, Milena Bond, Elvis Hysa

Ann Rheum Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis.
Victoria Konzett, Andreas Kerschbaumer, Josef S Smolen, Daniel Aletaha

Ann Rheum Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definition of rheumatoid arthritis flare based on SDAI and CDAI.
Victoria Konzett, Andreas Kerschbaumer, Josef S Smolen, Eirik Klami Kristianslund, Sella A Provan

Ann Rheum Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, Kamran Ghoreschi, Massimo Gadina

Ann Rheum Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis.
Andreas Kerschbaumer, Nina Maria Stimakovits, Josef S Smolen, Tijen Stefanova, Eva Chwala

Ann Rheum Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.
Felix Kartnig, Daniel Mrak, Elisabeth Simader, Selma Tobudic, Helga Radner, Andreas Kerschbaumer

Ann Rheum Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Josef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano

Ann Rheum Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde

Ann Rheum Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde

Ann Rheum Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Désirée van der Heijde, Roberto Caporali

Ann Rheum Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.
Daniel Mrak, Elisabeth Simader, Daniela Sieghart, Peter Mandl, Helga Radner, Andreas Kerschbaumer

Ann Rheum Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The greatest air quality experiment ever: Policy suggestions from the COVID-19 lockdown in twelve European cities.
Marialuisa Volta, Umberto Giostra, Giorgio Guariso, Jose Baldasano, Martin Lutz, Andreas Kerschbaumer

PLoS One· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.
Daniel Mrak, Daniela Sieghart, Elisabeth Simader, Selma Tobudic, Helga Radner, Andreas Kerschbaumer

Nat Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.
Kastriot Kastrati, Daniel Aletaha, Gerd R Burmester, Eva Chwala, Christian Dejaco, Andreas Kerschbaumer

RMD Open· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis